Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 1/20 | 0.59 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | PER2 | O15055 | 3/20 | 0.41 |
| ▸ | CRY1 | Q16526 | 3/20 | 0.41 |
| ▸ | CRY2 | Q49AN0 | 3/20 | 0.41 |
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447814 | 1.00 | GBA1 (0.59) | GBA1CCR1PER2CRY1CRY2 | |
| SCHEMBL4136570 | 0.87 | TRPV4 (0.49) | GBA1CCR1TRPV4TDO2 | |
| SCHEMBL5433686 | 0.86 | GBA1 (0.55) | GBA1CCR1TRPV4ATM | |
| SCHEMBL14360908 | 0.86 | GBA1 (0.55) | GBA1CCR1TRPV4ATM | |
| SCHEMBL5436530 | 0.78 | BRD4 (0.48) | GBA1CCR1PER2CRY1CRY2 | |
| SCHEMBL5436535 | 0.78 | BRD4 (0.48) | GBA1CCR1PER2CRY1CRY2 | |
| SCHEMBL14360846 | 0.76 | CCR1 (0.52) | CCR1TRPV4ALDH1A1PKMTDO2 | |
| SCHEMBL4140210 | 0.75 | BMP1 (0.45) | GBA1CCR1PER2CRY1CRY2 | |
| SCHEMBL4140203 | 0.75 | ADAM17 (0.42) | GBA1CCR1PER2CRY1CRY2 | |
| SCHEMBL13872427 | 0.75 | HTT (0.45) | CCR1PER2CRY1CRY2TRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | SMITHKLINE BEECHAM CORPORATION | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259965-A1 | Acyclic 1,3-Diamine And Uses Therefor | TRPV4, TRPC4, TRPV1 | GBA1 1769/4885CCR1 511/4885PER2 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.